Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • YC-1: A Dual HIF-1α Inhibitor & sGC Activator for Cancer ...

    2026-03-07

    Harnessing YC-1: Dual-Action HIF-1α Inhibitor and sGC Activator in Cancer and Hypoxia Pathway Research

    Overview: Principle and Mechanistic Foundation

    YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule that stands out in cancer research and hypoxia signaling pathway investigations due to its unique dual actions: potent inhibition of hypoxia-inducible factor 1α (HIF-1α) and robust activation of soluble guanylyl cyclase (sGC). Originally developed as a HIF-1α inhibitor, YC-1 blocks transcriptional activity associated with the oxygen-sensing pathway, suppressing key genes involved in tumor survival, angiogenesis, and metastasis under hypoxic conditions. Simultaneously, YC-1’s sGC activation triggers the cGMP signaling pathway, offering added utility in studies of vascular biology, platelet aggregation, and apoptosis.

    In vitro, YC-1’s effect on HIF-1α is quantified by an IC50 of 1.2 μM for inhibition of hypoxia-induced HIF-1 transcriptional activity, while in vivo studies demonstrate reduced tumor vascularization and growth across multiple cancer models. The high purity (≥98%) and DMSO/ethanol solubility profile (≥30.4 mg/mL in DMSO, ≥16.2 mg/mL in ethanol) provided by APExBIO ensures consistent results for bench scientists seeking to dissect the interplay between hypoxia, angiogenesis, and apoptosis in cancer biology research.

    Step-by-Step Experimental Workflow Enhancements with YC-1

    1. Reagent Preparation and Storage

    • Dissolution: Prepare fresh stock solutions by dissolving YC-1 in DMSO or ethanol to desired concentrations (e.g., 10–30 mM). Due to insolubility in water, avoid aqueous preparations except for immediate dilution into working solutions.
    • Aliquoting: Aliquot stock solutions to minimize freeze-thaw cycles. Store at room temperature, and use promptly—long-term storage of solutions is not recommended to preserve compound integrity.

    2. In Vitro Hypoxia and Cytotoxicity Assays

    • Cell Model Selection: Employ human or murine cancer cell lines (e.g., HepG2, MCF7, A549) cultured under normoxic and hypoxic conditions (1% O2) to model the tumor microenvironment.
    • Treatment Protocol: Treat cells with serial dilutions of YC-1 (0.5–10 μM) for 12–48 hours. For hypoxia, pre-equilibrate cells in hypoxic chambers before compound addition for maximal HIF-1α stabilization.
    • Assay Readouts: Quantify HIF-1α protein levels by Western blot or ELISA, and assess transcriptional activity using HRE-luciferase reporter assays. For proliferation/apoptosis, use MTT, Annexin V/PI, or caspase activation kits.

    3. In Vivo Tumor Angiogenesis and Growth Studies

    • Animal Models: Inject YC-1 (5–25 mg/kg, intraperitoneally) in xenograft or syngeneic mouse tumor models.
    • Endpoints: Measure tumor volume, vascular density (CD31 immunohistochemistry), and HIF-1α target gene expression (e.g., VEGF, GLUT1) post-treatment. Published studies consistently report smaller, less vascularized tumors upon YC-1 exposure.

    4. cGMP Signaling and Vascular Function Assays

    • Leverage YC-1’s sGC activation to study cGMP accumulation in smooth muscle or endothelial cells. Measure cGMP levels using ELISA following YC-1 stimulation (1–10 μM, 10–30 min incubation).
    • Investigate downstream effects such as vasorelaxation or inhibition of platelet aggregation using organ bath or aggregometry assays, respectively.

    Advanced Applications and Comparative Advantages

    YC-1’s dual-action profile delivers unique experimental flexibility compared to single-target HIF-1α inhibitors or sGC activators. In cancer research, YC-1 enables rigorous dissection of the cross-talk between hypoxia signaling and cGMP-mediated cellular responses. For example, its ability to simultaneously inhibit HIF-1α and promote cGMP synthesis allows researchers to parse out the relative contributions of hypoxia and nitric oxide pathways in tumor angiogenesis inhibition and apoptosis induction.

    In comparative studies, YC-1-treated tumors exhibited a significant reduction in both size and vascularization—outperforming classic sGC activators (which lack direct HIF-1α inhibition) and providing a multi-modal approach to anticancer drug targeting hypoxia-inducible factor 1. As detailed in "YC-1: Soluble Guanylyl Cyclase Activator for Advanced Cancer Research", this dual mechanism is a distinguishing feature that elevates YC-1 as a staple in apoptosis and cancer biology research workflows.

    Moreover, the "Optimizing Hypoxia and Cytotoxicity Assays with YC-1" review provides actionable guidance on integrating YC-1 into cell viability and mitochondrial quality control assays, demonstrating reproducibility and mechanistic clarity in hypoxia signaling pathway studies. These works complement the practical protocol enhancements outlined here, while "YC-1: A Dual-Action HIF-1α Inhibitor and Soluble Guanylyl Cyclase Activator" offers atomic-level mechanistic insights for advanced users.

    Troubleshooting and Optimization Tips

    Solubility and Handling

    • Always use anhydrous DMSO or ethanol for stock preparation and avoid water to prevent precipitation. Prepare working dilutions freshly, as prolonged storage leads to degradation and loss of activity.
    • For in vivo work, dilute DMSO stocks into physiological saline or media immediately prior to administration, ensuring final DMSO concentration does not exceed 0.1–0.5% (to avoid cytotoxicity).

    Assay Sensitivity and Specificity

    • In luciferase or reporter assays, titrate YC-1 to identify the minimal effective concentration. Excess YC-1 may trigger off-target effects due to sGC activation.
    • Monitor for potential cross-reactivity in multiplexed assays; consider including YC-1-only controls to account for any intrinsic fluorescence or signal interference, especially in spectrofluorimetric readouts.
    • The reference study on micellar matrix-enhanced spectrofluorimetry demonstrates that environmental factors such as surfactant presence can dramatically impact sensitivity. While YC-1 is not fluorescently active like the drugs in the study, similar principles apply: controlling matrix composition enhances analytical accuracy and reproducibility.

    Biological Variability

    • If inconsistent HIF-1α inhibition is observed, verify hypoxic conditions in cell culture using O2 probes or hypoxia marker dyes.
    • Include vehicle and positive controls (e.g., DMOG for HIF-1α stabilization) to benchmark YC-1 performance across experimental runs.

    Future Outlook: Expanding the Reach of YC-1 in Translational Research

    With its validated dual-action profile, YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, available from APExBIO, is positioned to play a pivotal role in next-generation translational research. Ongoing studies are investigating combinations of YC-1 with immune checkpoint inhibitors, anti-angiogenic agents, and metabolic modulators to synergistically target tumor hypoxia and vascular remodeling. The compound’s unique ability to modulate both the oxygen-sensing and cGMP signaling pathways is expected to yield new insights into tumor microenvironment adaptation, resistance mechanisms, and therapeutic vulnerabilities.

    Emerging applications also include exploring YC-1’s impact on lower urinary tract symptoms and vascular function, as inspired by methodologies like those described in the recent spectrofluorimetric study. By leveraging micellar matrices or advanced analytical platforms, researchers can further enhance the sensitivity and selectivity of YC-1 quantitation in biological samples, paving the way for pharmacokinetic and translational investigations.

    Conclusion

    YC-1 is a premier tool for dissecting the molecular underpinnings of tumor angiogenesis, apoptosis, and hypoxia signaling. Its reproducible inhibition of hypoxia-inducible factor 1 transcriptional activity and robust sGC activation enable advanced cancer research and mechanistic studies. For scientists demanding reliability and high purity, APExBIO delivers YC-1 as a trusted research reagent, empowering innovation in the study of cancer biology and oxygen-sensing mechanisms.